Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
Lessening the economic burden of treating CLL
Importance of Bcl-2-targeted therapies
John Gribben et al.
An update on kinase inhibitors from EHA 2017
Mechanism of action of venetoclax (ABT-199) and its side effects